Novo Nordisk (NOVO) investor relations material

Executive summary

• Over 45 million people served with obesity and diabetes therapies, with more than 4 million using obesity treatments and over 1 million US patients on the WegovyⓇ pill since launch, marking a 50% year-over-year increase and over 2 million cumulative prescriptions.

• Launched WegovyⓇ pill in the US, achieving record-breaking uptake, and expanded the obesity portfolio globally with launches in over 55 countries and strong commercial access partnerships.

• Six regulatory approvals and over 10 clinical trial initiations in Q1 2026, including key obesity and diabetes therapies.

• Strategic investments in R&D and commercial initiatives totaled DKK 22–22.4 billion in Q1 2026.

• DKK 38 billion returned to shareholders via dividends and share buybacks in Q1 2026.

Financial highlights

• Q1 2026 reported sales: DKK 96.8 billion (+32% YoY), driven by a DKK 26.8 billion US 340B provision reversal; adjusted sales: DKK 70.1–83.2 billion (-4% at CER) due to lower realized prices.

• Adjusted gross margin: 80.6% (down from 83.5% in 2025); reported gross margin: 85.9%.

• Adjusted operating profit: DKK 32.9 billion (-6% at CER); reported operating profit: DKK 59.6 billion (+65% at CER).

• Net profit: DKK 48.6 billion (reported); adjusted net profit: DKK 29.5 billion (-3% YoY).

• Free cash flow: DKK 12.8 billion (+13% YoY); capital expenditure: DKK 11.3 billion (-16% YoY).

Outlook and guidance

• 2026 adjusted sales growth guidance raised to -4% to -12% at CER, with adjusted operating profit growth also at -4% to -12% at CER.

• Non-adjusted mid-point guidance: 1% sales growth and 12% operating profit growth at CER.

• Free cash flow for 2026 projected at DKK 36–46 billion; capital expenditure around DKK 55 billion; effective tax rate expected at 21–23%.

• Outlook reflects continued GLP-1 volume growth, market expansion, patent expiries, and competitive pressures.